A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants

Recruiting

Phase 1

Cabotegravir with HyaluronidaseA Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants

Sponsor:

ViiV Healthcare

Code:

NCT05418868

Conditions

HIV Infections

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Accepted

Interventions

Cabotegravir 200 mg/mL

Cabotegravir >=400 mg/mL

Cabotegravir Formulation I

CAB Formulation J

rHuPH20

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-08. This information was provided to ClinicalTrials.gov by ViiV Healthcare on 2025-06-29.